Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

As of June 30, 2024, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H carries a market capitalization of 143.55M, placing it among publicly traded companies globally. Its enterprise value stands at 256.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1.90B shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H recorded an income tax benefit of -1.12M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H's stock has declined approximately 55.13% over the past 52 weeks. The 50-day moving average sits at 0.23, while the 200-day moving average is 0.26.

As of June 30, 2024, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H holds 19.56M in cash and equivalents against 118.76M in total debt, resulting in a net debt position of 86.45M. Total book value stands at 49.24M, with working capital of -25.54M providing operational flexibility.